AMRUTANJAN:NSE-Amrutanjan Health Care Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 629.70

Change

+2.20 (+0.35)%

Market Cap

INR 18.67B

Volume

0.04M

Average Target Price

INR 670.00 (+6.40%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amrutanjan Health Care Limited produces and sells ayurvedic pain balms in India. It operates through OTC products, Beverages, and Others segments. The company offers pain management products, including pain balms and roll-ons; and back pain roll-ons and lotions, body pain gels, and joint muscle sprays, as well as non-steroidal anti-inflammatory drugs. It also provides congestion management products, such as cold rubs, cough syrups, nasal inhalers, and mints. In addition, the company offers sanitary napkins for women. Further, it provides corn caps; hand sanitizers; and juice drinks under the Fruitnik and Fruitnik Electro+ brand names, as well as operates a pain management center. It also exports its products to Gulf, African, South East, and Asian countries. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+38.25 (+5.93%)

INR1,570.24B 65.16 32.15
DIVISLAB:NSE Divi's Laboratories Limited

+50.10 (+1.26%)

INR1,079.16B 57.69 39.20
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+93.70 (+1.85%)

INR857.48B 40.33 20.86
CADILAHC:NSE Cadila Healthcare Limited

+32.55 (+5.72%)

INR595.15B 32.24 19.24
AUROPHARMA:NSE Aurobindo Pharma Limited

+61.55 (+6.43%)

INR571.52B 10.62 6.90
LUPIN:NSE Lupin Limited

+142.55 (+13.47%)

INR487.05B 42.59 17.31
ALKEM:NSE Alkem Laboratories Limited

+95.85 (+3.42%)

INR332.93B 21.71 15.10
IPCALAB:NSE Ipca Laboratories Limited

+6.35 (+0.30%)

INR267.20B 25.01 16.73
LAURUSLABS:NSE Laurus Labs Limited

+0.60 (+0.12%)

INR259.84B 26.47 16.11
APLLTD:NSE Alembic Pharmaceuticals Limite..

-50.30 (-5.00%)

INR195.73B 16.58 12.75

ETFs Containing AMRUTANJAN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.25% 75% C 73% C
Dividend Return 0.16% 10% F 6% F
Total Return 25.41% 75% C 73% C
Trailing 12 Months  
Capital Gain 73.04% 42% F 47% F
Dividend Return 0.44% 24% F 15% F
Total Return 73.48% 42% F 46% F
Trailing 5 Years  
Capital Gain 176.58% 75% C 83% B
Dividend Return 3.59% 71% C- 41% F
Total Return 180.17% 75% C 83% B
Average Annual (5 Year Horizon)  
Capital Gain 19.57% 60% D- 77% C+
Dividend Return 0.58% 60% D- 43% F
Total Return 20.15% 58% F 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 29.47% 92% A- 77% C+
Risk Adjusted Return 68.37% 63% D 93% A
Market Capitalization 18.67B 43% F 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.73 41% F 35% F
Price/Book Ratio 9.72 15% F 8% F
Price / Cash Flow Ratio 102.71 11% F 3% F
EV/EBITDA 25.18 22% F 26% F
Management Effectiveness  
Return on Equity 27.95% 93% A 95% A
Return on Invested Capital 11.13% 66% D 74% C
Return on Assets 14.89% 92% A- 97% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.80 51% F 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector